Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421623 | 0.77 | CRBN (0.32) | CRBN | |
| SCHEMBL1078392 | 0.74 | — | — | |
| SCHEMBL18551254 | 0.73 | — | — | |
| SCHEMBL14553236 | 0.72 | CRBN (0.31) | CRBN | |
| SCHEMBL948925 | 0.70 | — | — | |
| SCHEMBL67711 | 0.70 | — | — | |
| SCHEMBL1219806 | 0.69 | — | — | |
| SCHEMBL19225955 | 0.69 | — | — | |
| SCHEMBL6032573 | 0.69 | — | — | |
| SCHEMBL4420108 | 0.68 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55124767-A | — | — | None | — | — | JP | disclosed |
| CN-117865922-A | Formylcarboxylate coumarin compounds, methods of preparation and use thereof, and photoinitiator compositions containing same | 湖北固润科技股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-1436191-B | Antitumor ecteinascidin derivatives | PHARMA MAR SA | 2011-09-14 | — | — | CN | disclosed |
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-7919493-B2 | A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent | PHARMA MAR, S.A. (ES) | 2011-04-05 | — | — | US | disclosed |
| US-7524956-B2 | Hemisynthetic method and new compounds | PHARMA MAR, S.A. (ES) | 2009-04-28 | — | — | US | disclosed |
| CN-100475822-C | Synthesis method for producing ecteinascidin compound | PHARMA MAR SA (ES) | 2009-04-08 | — | — | CN | disclosed |
| US-7420051-B2 | Antitumor agents; microbiocides; antibiotics; forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction | PHARMA MAR, S.A. (ES) | 2008-09-02 | — | — | US | disclosed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | disclosed |
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | PHARMAMAR (ES) | 2008-06-19 | — | — | US | disclosed |
| WO-2001087894-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001077115-A1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2001-10-18 | — | — | WO | disclosed |
| WO-2000069862-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2000-11-23 | — | — | WO | disclosed |
| US-4237293-A | COLORFAST SHADES OF YELLOW TO RED FOR PLASTICS AND LACQUERS | CIBA-GEIGY CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4237286-A | COLORING PLASTICS AND LACQUERS IN YELLOW TO RED SHADES | CIBA-GEIGY CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| US-4237292-A | SHADES OF YELLOW TO RED FOR PLASTICS AND LACQUERS | CIBA-GEIGY CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
| JP-S55124767-A | 1,3-DIOXO-TETRAHYDROISOQUINOLINE DERIVATIVE AND ITS PREPARATION | YAMANOUCHI PHARMACEUT CO LTD | 1980-09-26 | — | — | JP | disclosed |
| US-4132708-A | Metal complexes of azomethines and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1979-01-02 | — | — | US | disclosed |
| US-4111947-A | DYES, PLASTICS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4022770-A | COLORING | CIBA-GEIGY CORPORATION (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146580-A1 | Anititumoral Ecteinascidin Derivatives | AREG, CD68, ASGR1 | CRBN 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.